Interventional device developer Boston Scientific of Natick, MA, has released nine-month results from its Taxus VI clinical trial at the 2004 Paris Course on Revascularization (PCR) this week in Paris.
The trial enrolled 448 patients at 44 sites in Europe, assessing the safety and efficacy of a moderate-release formulation paclitaxel-eluting stent in high-risk patients, including long lesions with overlapping stents, small vessels, and diabetics, the firm said.
The study data is consistent with earlier Taxus trials, the company said, supporting the conclusion that the moderate-release formulation in Taxus VI is as safe and effective as the slow-release formulation.
By AuntMinnie.com staff writersMay 26, 2004
Related Reading
Boston Scientific hails strong Taxus sales in U.S., May 18, 2004
Boston Scientific shows strong Q1 gains, April 20, 2004
Boston Scientific ups stake in Aspect, April 9, 2004
Boston Scientific launches Sentinol, April 8, 2004
FDA approves Boston Scientific fibroids treatment, March 30, 2004
Copyright © 2004 AuntMinnie.com
